Rallybio shares successful early-stage results for rare disease drug; new trial set for late 2026

Rallybio Corporation RLYB on Tuesday shared results from its Phase 1 confirmatory pharmacokinetic/pharmacodynamic (PK/PD) ...
The University of Manchester

Research identifies a distinct immune signature in treatment-resistant Myasthenia Gravis

Myasthenia Gravis (MG) is a rare autoimmune disease in which the immune system attacks the connection between nerves and ...